When Arbitration Agreement Provisions Time Travel: Illusory Promises and Continued At-Will Employment in Baker

First, this Note discusses the particular facts of the Baker case, including its procedural history and holding. Then, the history of salient cases and law is covered in three main areas related to Baker, specifically the concept of arbitrability, at-will employment’s status as effective consideration, and when courts find promises to be illusory. Following that, this Note summarizes the court’s decision in Baker and its lengthy and thorough dissent. Finally, this note discusses the significance of this case in relation to both the history of the topics involved and their application going forward

State Responses to the Tax Cuts and Jobs Act: An Analysis from Indiana and Missouri

This Article, authored by lawyers from the Indiana Department of Revenue and Missouri Department of Revenue, is intended to address, and hopefully add clarity to, the complexities of state taxation under the Tax Cuts and Jobs Act of 2017 (“TCJA”). After a brief historical and general overview of the TCJA, this Article focuses on seven distinct topics within the TCJA from a state perspective. These topics are: (1) Business Assets Expensing; (2) the TCJA’s treatment of 529 Accounts; (3) the 30% Business Interest Limitation; (4) the Transition Tax (also referred to as “Deemed Repatriation”); (5) GILTI, or Global Intangible Low-Taxed Income; (6) the elimination of the Personal and Dependency Exemption Deductions; and (7) the Qualified Business Income Deduction. For each topic, this Article gives an overview of the associated TCJA provisions, addresses some responses of the states to these provisions, and provides opportunity for discussion of possible or actual responses by Indiana and/or Missouri

Convergence of the Optimized Delta Expansion for the Connected Vacuum Amplitude -- Anharmonic Oscillator

The convergence of the linear $\delta$ expansion for the connected generating functional of the quantum anharmonic oscillator is proved. Using an order-dependent scaling for the variational parameter $\lambda$, we show that the expansion converges to the exact result with an error proportional to $\exp(-cN^{1/3})$.Comment: LaTeX, 14 pages, 4 figures

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity than ibrutinib. We evaluated the safety and efficacy of 100 mg of acalabrutinib twice daily or 200 mg once daily in patients with CLL who discontinued ibrutinib because of intolerance as determined by the investigators. Among 33 treated patients (61% men; median age, 64 years; range, 50-82 years), median duration of prior ibrutinib treatment was 11.6 months (range, 1-62 months); median time from ibrutinib discontinuation to acalabrutinib start was 47 days (range, 3-331 days). After a median of 19.0 months (range, 0.2-30.6 months), 23 patients remained on acalabrutinib; 10 had discontinued (progressive disease, n = 4; AEs, n = 3). No acalabrutinib dose reductions occurred. During acalabrutinib treatment, the most frequent AEs included diarrhea (58%), headache (39%), and cough (33%). Grade 3/4 AEs occurred in 58%, most commonly neutropenia (12%) and thrombocytopenia (9%). Of 61 ibrutinib-related AEs associated with intolerance, 72% did not recur and 13% recurred at a lower grade with acalabrutinib. Overall response rate was 76%, including 1 complete and 19 partial responses and 5 partial responses with lymphocytosis. Among 25 responders, median duration of response was not reached. Median progression-free survival (PFS) was not reached; 1-year PFS was 83.4% (95% confidence interval, 64.5%-92.7%). Acalabrutinib was well tolerated with a high response rate in patients who were previously intolerant to ibrutinib. This trial was registered at www.clinicaltrials.gov as #NCT02029443

Stellar Population Trends in S0 Galaxies

We present stellar population age and metallicity trends for a sample of 59 S0 galaxies based on optical SDSS and NIR J & H photometry. When combined with optical g and r passband imaging data from the SDSS archive and stellar population models, we obtain radial age and metallicity trends out to at least 5 effective radii for most of the galaxies in our sample. The sample covers a range in stellar mass and light concentration. We find an average central light-weighted age of ~ 4 Gyr and central metallicity [Z/H] ~ 0.2 dex. Almost all galaxies show a negative metallicity gradient from the center out, with an average value of Delta[Z/H]/Delta(log(r/Re)) = -0.6. An age increase, decrease, and minimal change with radius is observed for 58%, 19%, and 23%, respectively, for a mean age gradient of Delta(age)/Delta(log(r/Re)) = 2.3 Gyr dex^{-1}. For 14 out of 59 galaxies, the light-weighted age of the outer region is greater than 10 Gyr. We find that galaxies with both lower mass and lower concentration have younger light-weighted ages and lower light-weighted metallicities. This mass-metallicity relation extends into the outer regions of our S0 galaxies. Our results are consistent with the formation of S0 galaxies through the transformation of spiral galaxy disks. Determining the structural component that makes up the outer region of galaxies with old outksirts is a necessary step to understand the formation history of S0 galaxies.Comment: accepted to MNRA

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002

To improve long-term outcomes for Burkitt leukaemia/lymphoma (BL) or aggressive lymphomas in adults, we assessed the benefit of adding rituximab and filgrastim support to a dose-dense modified chemotherapy regimen from the Cancer and Leukemia Group B (CALGB) 9251 trial. One hundred and five patients (aged 19–79 years) were enrolled; 27% were >60 years old; 47% had high or high-intermediate risk by International Prognostic Index (IPI) criteria. Common severe toxicities included stomatitis/upper gastrointestinal toxicity (69%), renal insufficiency (10%), neurological events (25%) and pulmonary events (18%). Seven died from treatment-related causes (1 central nervous system bleed, 4 infections, 2 respiratory failure); 5 were > 60 years old. Results in this adult population are encouraging as complete response (CR) was observed in 83% and 4-year event-free (EFS) and overall survivals (OS) were 74% and 78%, respectively. Results compare favourably to our prior chemotherapy alone study (CALGB 9251) but despite this, high-risk patients still had worse outcomes. In conclusion, short duration, intensive chemo-immunotherapy is feasible and should be considered in adults with BL as it results in high remission rates and durable remissions